Hematology Toxicities in Paclitaxel-Carboplatin Cancer Regiment

Annisa Diyan Meitasari; Dian Eka Ermawati; Sholichah Rohmani; Heru Sasongko; Muhammad Fiqri Zulpadly; Diyah Tri Utami; Nindita Clourisa Amaris Susanto; Meta Kartika Untari; Ulfa Afrinurfadhilah Darojati

doi:10.24071/jpsc.007064

Hematology Toxicities in Paclitaxel-Carboplatin Cancer Regiment

Annisa Diyan Meitasari^(1*), Dian Eka Ermawati⁽²⁾, Sholichah Rohmani⁽³⁾, Heru Sasongko⁽⁴⁾, Muhammad Fiqri Zulpadly⁽⁵⁾, Diyah Tri Utami⁽⁶⁾, Nindita Clourisa Amaris Susanto⁽⁷⁾, Meta Kartika Untari⁽⁸⁾, Ulfa Afrinurfadhilah Darojati⁽⁹⁾,

(1) Sebelas Maret University
(2) Sebelas Maret University
(3) Sebelas Maret University
(4) Sebelas Maret University
(5) Sebelas Maret University
(6) Sebelas Maret University
(7) Sebelas Maret University
(8) Sebelas Maret University
(9) Sebelas Maret University
(*) Corresponding Author

Abstract

Chemotherapy is one of therapy for patients with cancer. Treatment carboplatin paclitaxel regimen is usually use for cervix, breast, and ovarium cancer. But the data of ADRs in hematology toxicity caused paclitaxel-carboplatin regiment is minimal, so it is required to do research. The aim of this research is can give information about the hematology toxicity, incident, severity, relationship between risk factor due incident of myelosuppression, and relationship between pre post chemotherapy due the myelosuppression. The severity ADRs use CTCAE 5.0. The ADRs were evaluated by severity, descriptive statistics, and some bivariate analysis. Anemia (66.46%) has a highest incident and followed by leukopenia (18.18%), neutropenia (13.22%), and thrombocytopenia (9.09%). Type of cancer associate with incident of anemia, leukopenia, and thrombocytopenia. The number of cycle chemotherapy use carboplatin paclitaxel regiments affects significant with the incidence of anemia. Patients who use paclitaxel-carboplatin as a regimen chemotherapy confirmed decrease in hematologic data such as hemoglobin, leukocyte, and thrombocyte.

Full Text:

PDF

References

Amjad, MT., Chidharla, A., and Kasi, A. 2023. Cancer Chemotherapy. In Cancer Chemotherapy (NCBI Bookshelf) (pp. 1–17). StatPearls Publishing.

Assi, S., Torrington, E., Cheema, E., and Hamid, A. Al. 2021. Adverse drug reactions associated with chemotherapeutic agents used in breast cancer: Analysis of patients’ online forums. Journal of Oncology Pharmacy Practice, 27(1), 108–118.

Bryer, E., and Henry, D. 2018. Chemotherapy-induced anemia: Etiology, pathophysiology, and implications for contemporary practice. International Journal of Clinical Transfusion Medicine, Volume 6, 21–31.

Cannavale, K., Xu, H., Xu, L., Sattayapiwat, O., Rodriguez, R., Bohac, C., Page, J., and Chao, C. 2019. Epidemiology of chemotherapy-induced anemia in patients with non-Hodgkin lymphoma. The Permanente Journal, 23.

Chan, J. K., Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., DiSilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., Huh, W. K., O’Malley, D. M., Boente, M. P., Michael, H., and Monk, B. J. 2016. Weekly vs. Every-3-Week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine, 374(8), 738–748.

Charles, A., Dewayani, B. M., Sahiratmadja, E., Winarno, G. N. A., and Susanto, H. 2016. Paclitaxel-carboplatin chemotherapy induced hematologic toxicities among epithelial ovarian cancer patients. Universa Medicina, 35(3), 165.

Dechow, T., Riera-Knorrenschild, J., Hackanson, B., Janssen, J., Schulz, H., Chiabudini, M., Fischer von Weikersthal, L., Budweiser, S., Nacke, A., Taeuscher, D., Welslau, M., and Potthoff, K. 2021. First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN Study. Cancer Medicine, 10(22), 8127–8137.

Garces, Á. H. I., Mora, P. A. R., Alves, F. V. G., Do Carmo, C. C., Grazziotin, R., Fernandes, A. C. F. M., Nogueira-Rodrigues, A., and De Melo, A. C. 2013. First-line paclitaxel and carboplatin in persistent/recurrent or advanced cervical cancer: A retrospective analysis of patients treated at Brazilian National Cancer Institute. International Journal of Gynecological Cancer, 23(4), 743–748.

Hart, L., Ogbonnaya, A., Boykin, K., Deyoung, K., Bailey, R., Heritage, T., Lopez-Gonzalez, L., Huang, H., and Gordan, L. 2023. Burden of Chemotherapy-Induced myelosuppression among patients with extensive-stage small cell lung cancer: A retrospective study from community oncology practices. Cancer Medicine, 12, 10020–10030.

Huang, C. Y., Cheng, M., Lee, N. R., Huang, H. Y., Lee, W. L., Chang, W. H., and Wang, P. H. 2020. Comparing paclitaxel-"carboplatin with paclitaxel-"cisplatin as the front-line chemotherapy for patients with FIGO IIIC serous-type tubo-ovarian cancer. International Journal of Environmental Research and Public Health, 17(7).

Jin, H., Chen, X., Liu, Q., Wei, Z., and LI, J. 2016. Risk factors for chemotherapy-induced leukopenia in patients with lung cancer. International Journal of Clinical Medicine, 7(3), 225–230.

Keziah, D., Bindhiya, M., Jayaprakash, M., and Prudence, R. A. 2023. Prospective observational study on the risk factors of chemotherapy-induced myelosuppression and its management in a tertiary care hospital. Indian Journal of Medical and Paediatric Oncology, 45, 416-421.

Kuter, D. J. 2022. Treatment of chhemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. In Haematologica, 107(6), 1243–1263.

Lee, J. H., Jang, E., Jung, M. H., Ha, K. T., and Han, C. 2016. Clinical effectiveness of acupuncture in the treatment of chemotherapy-induced leukopenia: A systematic review. European Journal of Integrative Medicine, 8(5), 802–808.

Liu, W., Zhang, C. C., and Li, K. 2013. Prognostic value of chemotherapy-induced leukopenia in small-cell lung cancer. Cancer Biology and Medicine, 10(2), 92–98.

Lobefaro, R., Mariani, L., Peverelli, G., Ligorio, F., Fucà, G., Rametta, A., Zattarin, E., Leporati, R., Presti, D., Cantarelli, B., Depretto, C., Vingiani, A., Manoukian, S., Scaperrotta, G., Bianchi, G. V., Capri, G., Pruneri, G., de Braud, F., and Vernieri, C. 2023. Efficacy and safety of first-line carboplatin-paclitaxel and carboplatin-gemcitabine in patients with advanced triple-negative breast cancer: A monocentric, retrospective comparison. Clinical Breast Cancer, 35(3), 165-170.

Madeddu, C., Gramignano, G., Astara, G., Demontis, R., Sanna, E., Atzeni, V., and Macciò, A. 2018. Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach. Frontiers in Physiology, 9,.

Meitasari, A. D., Sutrisna, E., and Cholisoh, Z. 2021. Neurotoxicity effect in cancer regimen carboplatin-paclitaxel. Asian Journal of Pharmaceutical and Clinical Research, 14(10), 68–70.

Noviyani, R., Indrayathi, P. A., Budiana, I. N. G., Niruri, R., Tunas, K., and Adnyani, N. M. D. D. 2019. Effect of paclitaxel-cisplatin chemotherapy towards hemoglobin, platelet, and leukocyte levels in epithelial ovarian cancer patients. Journal of Applied Pharmaceutical Science, 9(1), 104–107.

Oun, R., Moussa, Y. E., and Wheate, N. J. 2018. The Side Effects of Platinum-Based Chemotherapy Drugs: A Review for Chemists. Dalton Transactions, 47(19), 6645–6653).

Paniroi, B. V., and Nuryanto, K. H. 2015. Myelosuppression Effect on Ovarian Cancer Patient with Carboplatin and Paclitaxel Adjuvant Chemotherapy at RSUPN Dr. Cipto Mangunkusumo: An Analysis of Haemoglobin, Leukocyte, and Thrombocyte Level [Thesis]. Universitas Indonesia.

Pilleron, S., Sarfati, D., Janssen-Heijnen, M., Vignat, J., Ferlay, J., Bray, F., and Soerjomataram, I. 2019. Global cancer incidence in older adults, 2012 and 2035: A population-based study. International Journal of Cancer, 144(1), 49–58.

Pourali, L., Taghizadeh, A., Akhoundi, M. R., Varshoei, F., Zarifian, A., and Andalibi, M. S. S. 2017. Frequency of chemotherapy induced anemia in breast cancer patients. International Journal of Cancer Management, 10(1).

Sharma, P., Georgy, J. T., Andrews, A. G., John, A. O., Joel, A., Chacko, R. T., Premkumar, P. S., and Singh, A. 2022. Anemia requiring transfusion in breast cancer patients on dose-dense chemotherapy: Prevalence, risk factors, cost and effect on disease outcome. Supportive Care in Cancer, 30(6), 5519–5526.

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., and Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.

Winarto, H., Wijaya, A., Kunci, K., and Penelitian, A. 2020. Gambaran mielosupresi pada pasien kanker ovarium yang menerima kemoterapi carboplatin-paclitaxel di RSUPN Cipto Mangunkusumo Tahun 2018. Journal Indonesia Medica Association (IDI), 70(4), 59–64.

Workalemahu, G., Abdela, O. A., and Yenit, M. K. 2020. Chemotherapy-related adverse drug reaction and associated factors among hospitalized paediatric cancer patients at hospitals in North-West Ethiopia. Drug, Healthcare and Patient Safety, 12, 195–205.

Xu, H., Xu, L., Page, J. H., Sattayapiwat, O., Rodriguez, R., and Chao, C. 2014. Incidence of chemotherapy induced anemia in patients diagnosed with solid tumors. Blood, 124(21), 4822–4822.

Yuliandra, Y., Nasif, H., Ermayanti, S., Sulistyowati, L., and Juwita, D. A. 2019. Hematologic toxicities of chemotherapy in lung cancer patients: A retrospective study in Dr. M. Djamil Hospital Padang, Indonesia. Indonesian Journal of Clinical Pharmacy, 8(2), 129.

DOI: https://doi.org/10.24071/jpsc.007064